Acalabrutinib - αποτελεσματα

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

calquence film-coated tablet 100mg

astrazeneca singapore pte ltd - acalabrutinib maleate eqv acalabrutinib - tablet, film coated - acalabrutinib maleate eqv acalabrutinib 100mg

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

calquence

astrazeneca limited - acalabrutinib 100mg - capsule - 100 mg - active: acalabrutinib 100mg excipient: black ink (calquence) gelatin indigo carmine iron oxide yellow magnesium stearate silicified microcrystalline cellulose sodium starch glycolate starch titanium dioxide - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. calquence is indicated for the treatment of patients with chronic lymphocytic leukaemia (cll)/small lymphocytic lymphoma (sll).

Νέα Ζηλανδία - Αγγλικά - Medsafe (Medicines Safety Authority)

calquence

astrazeneca limited - acalabrutinib maleate monohydrate 129mg equivalent to acalabrutinib free base 100 mg - film coated tablet - 100 mg - active: acalabrutinib maleate monohydrate 129mg equivalent to acalabrutinib free base 100 mg excipient: copovidone hyprolose hypromellose iron oxide red iron oxide yellow macrogol 3350 mannitol medium-chain triglycerides microcrystalline cellulose purified water sodium stearyl fumarate titanium dioxide - calquence is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

calquence hard capsules 100mg

astrazeneca singapore pte ltd - acalabrutinib - capsule - acalabrutinib 100mg